InvestorsHub Logo
Post# of 252186
Next 10
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

Re: None

Wednesday, 05/23/2012 4:08:16 PM

Wednesday, May 23, 2012 4:08:16 PM

Post# of 252186
CLDX PR:

Key quotes for this interim look:

In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed (CDX-011 ORR of 36%; IC ORR of 0%)



In patients with both triple negative breast cancer and high GPNMB expression, a statistically significant PFS benefit is currently observed (p=0.0032)



(Caution these subgroup numbers are very small).

Not slam-dunk results, but pretty intriguing - stock is down a bit AH so who knows what the market was hoping for.

http://ir.celldextherapeutics.com/phoenix.zhtml?c=93243&p=irol-newsArticle&ID=1699241&highlight=

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.